-
1
-
-
0035069606
-
The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey
-
Krueger G, Koo J, Lebwohl M, et al,. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4.
-
(2001)
Arch Dermatol
, vol.137
, pp. 280-284
-
-
Krueger, G.1
Koo, J.2
Lebwohl, M.3
-
2
-
-
70350343375
-
Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and meta-analysis
-
Bansback N, Sizto S, Sun H, et al,. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009; 219: 209-18.
-
(2009)
Dermatology
, vol.219
, pp. 209-218
-
-
Bansback, N.1
Sizto, S.2
Sun, H.3
-
3
-
-
24944542391
-
Traditional systemic treatments have not fully met the needs of psoriasis patients: Results from a national survey
-
Nijsten T, Margolis DJ, Feldman SR, et al,. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005; 52: 434-44.
-
(2005)
J Am Acad Dermatol
, vol.52
, pp. 434-444
-
-
Nijsten, T.1
Margolis, D.J.2
Feldman, S.R.3
-
4
-
-
1842555395
-
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction
-
Stern RS, Nijsten T, Feldman SR, et al,. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
-
(2004)
J Investig Dermatol Symp Proc
, vol.9
, pp. 136-139
-
-
Stern, R.S.1
Nijsten, T.2
Feldman, S.R.3
-
5
-
-
43449111187
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
-
Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
-
(2008)
Lancet
, vol.371
, pp. 1665-1674
-
-
Leonardi, C.L.1
Kimball, A.B.2
Papp, K.A.3
-
6
-
-
43449139402
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
-
Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
-
(2008)
Lancet
, vol.371
, pp. 1675-1684
-
-
Papp, K.A.1
Langley, R.G.2
Lebwohl, M.3
-
7
-
-
84900485940
-
Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: Results from a randomized phase III study
-
Papp KA, Sundaram M, Bao Y, et al,. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol 2013; 28: 790-8.
-
(2013)
J Eur Acad Dermatol Venereol
, vol.28
, pp. 790-798
-
-
Papp, K.A.1
Sundaram, M.2
Bao, Y.3
-
8
-
-
84855938590
-
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis
-
Gordon KB, Langley RG, Gottlieb AB, et al,. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012; 132: 304-14.
-
(2012)
J Invest Dermatol
, vol.132
, pp. 304-314
-
-
Gordon, K.B.1
Langley, R.G.2
Gottlieb, A.B.3
-
9
-
-
33751546237
-
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis
-
Chan JR, Blumenschein W, Murphy E, et al,. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577-87.
-
(2006)
J Exp Med
, vol.203
, pp. 2577-2587
-
-
Chan, J.R.1
Blumenschein, W.2
Murphy, E.3
-
10
-
-
59149106117
-
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways
-
Nair RP, Duffin KC, Helms C, et al,. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41: 199-204.
-
(2009)
Nat Genet
, vol.41
, pp. 199-204
-
-
Nair, R.P.1
Duffin, K.C.2
Helms, C.3
-
11
-
-
84929359284
-
Clinical improvement in psoriasis with specific targeting of interleukin (IL)-23
-
Kopp T, Riedl E, Bangert C, et al,. Clinical improvement in psoriasis with specific targeting of interleukin (IL)-23. Nature 2015; 521: 222-6.
-
(2015)
Nature
, vol.521
, pp. 222-226
-
-
Kopp, T.1
Riedl, E.2
Bangert, C.3
-
12
-
-
84897146802
-
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
-
Sofen H, Smith S, Matheson RT, et al,. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014; 133: 1032-40.
-
(2014)
J Allergy Clin Immunol
, vol.133
, pp. 1032-1040
-
-
Sofen, H.1
Smith, S.2
Matheson, R.T.3
-
13
-
-
0037313578
-
Interleukin-12 and the regulation of innate resistance and adaptive immunity
-
Trinchieri G,. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-46.
-
(2003)
Nat Rev Immunol
, vol.3
, pp. 133-146
-
-
Trinchieri, G.1
-
14
-
-
34548133583
-
Development, cytokine profile and function of human interleukin 17-producing helper T cells
-
Wilson NJ, Boniface K, Chan JR, et al,. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-7.
-
(2007)
Nat Immunol
, vol.8
, pp. 950-957
-
-
Wilson, N.J.1
Boniface, K.2
Chan, J.R.3
-
15
-
-
77958072084
-
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis
-
Hueber W, Patel DD, Dryja T, et al,. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
-
(2010)
Sci Transl Med
, vol.2
, pp. 52ra72
-
-
Hueber, W.1
Patel, D.D.2
Dryja, T.3
-
16
-
-
84862860846
-
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
-
Krueger JG, Fretzin S, Suarez-Farinas M, et al,. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012; 130: 145-54.
-
(2012)
J Allergy Clin Immunol
, vol.130
, pp. 145-154
-
-
Krueger, J.G.1
Fretzin, S.2
Suarez-Farinas, M.3
-
17
-
-
78650706586
-
Cutting edge: A critical functional role for IL-23 in psoriasis
-
Tonel G, Conrad C, Laggner U, et al,. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 2010; 185: 5688-91.
-
(2010)
J Immunol
, vol.185
, pp. 5688-5691
-
-
Tonel, G.1
Conrad, C.2
Laggner, U.3
-
18
-
-
33750450544
-
Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection
-
Chackerian AA, Chen SJ, Brodie SJ, et al,. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect Immun 2006; 74: 6092-9.
-
(2006)
Infect Immun
, vol.74
, pp. 6092-6099
-
-
Chackerian, A.A.1
Chen, S.J.2
Brodie, S.J.3
-
19
-
-
78149491862
-
IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans
-
Kagami S, Rizzo HL, Kurtz SE, et al,. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol 2010; 185: 5453-62.
-
(2010)
J Immunol
, vol.185
, pp. 5453-5462
-
-
Kagami, S.1
Rizzo, H.L.2
Kurtz, S.E.3
-
20
-
-
71849109959
-
Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17
-
Schulz SM, Kohler G, Schutze N, et al,. Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol 2008; 181: 7891-901.
-
(2008)
J Immunol
, vol.181
, pp. 7891-7901
-
-
Schulz, S.M.1
Kohler, G.2
Schutze, N.3
-
21
-
-
84865116628
-
Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state
-
Teng MW, Vesely MD, Duret H, et al,. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 2012; 72: 3987-96.
-
(2012)
Cancer Res
, vol.72
, pp. 3987-3996
-
-
Teng, M.W.1
Vesely, M.D.2
Duret, H.3
-
22
-
-
84868613705
-
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
-
Grivennikov SI, Wang K, Mucida D, et al,. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-8.
-
(2012)
Nature
, vol.491
, pp. 254-258
-
-
Grivennikov, S.I.1
Wang, K.2
Mucida, D.3
-
24
-
-
33746534417
-
IL-23 promotes tumour incidence and growth
-
Langowski JL, Zhang X, Wu L, et al,. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461-5.
-
(2006)
Nature
, vol.442
, pp. 461-465
-
-
Langowski, J.L.1
Zhang, X.2
Wu, L.3
-
25
-
-
33645519047
-
Enhanced photocarcinogenesis in interleukin-12-deficient mice
-
Maeda A, Schneider SW, Kojima M, et al,. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res 2006; 66: 2962-9.
-
(2006)
Cancer Res
, vol.66
, pp. 2962-2969
-
-
Maeda, A.1
Schneider, S.W.2
Kojima, M.3
|